CENBF.US CEN Biotech Inc
- Market cap
- USD 6.53K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is CENBF.US undervalued?
Graham numberThe Graham number of CEN Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CEN Biotech Inc fundamental analysis
No fundamental analysis for CEN Biotech Inc yet.
CEN Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CEN Biotech Inc
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.
Full company profileCEN Biotech Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
CEN Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 2.32K | 0.00 | 0.00 | 0.00 | 0.00 | 627K | 987K | 415K |
| Gross Profit | - | - | - | -141K | -11.6M | -4.37M | -2.58M | -436K | 627K | 498K | 377K |
| Operating Income | -571K | -3.01M | -1.05M | -1.19M | -11.6M | -3.10M | -2.58M | -2.21M | -19.0M | -1.27M | -1.77M |
| EBITDA | 571K | -3.01M | -1.05M | -6.49M | -11.3M | -4.22M | -1.90M | 18.4M | -17.6M | -773K | -149K |
| Net Income | -571K | -3.16M | -2.41M | -7.58M | -14.1M | -7.53M | -5.66M | 14.2M | -18.9M | -1.52M | -339K |
| EPS | -0.08 | -0.45 | -0.34 | -0.92 | -1.68 | -0.30 | -0.21 | 0.44 | -0.45 | -0.02 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | - | 8.46M | 8.30M | 4.09M | 9.02M | 7.31M | 7.30M | 6.31M | 8.44M | 7.86M | 8.09M |
| Total Liabilities | 238K | 11.9M | 14.1M | 17.5M | 28.0M | 28.6M | 32.8M | 16.3M | 10.1M | 10.2M | 10.6M |
| Shareholders' Equity | -238K | -3.40M | -5.81M | -13.4M | -19.0M | -21.3M | -25.5M | -9.99M | -1.66M | -2.29M | -2.53M |
| Cash & Short-term Investments | - | 44.4K | 3.02K | 62.4K | 85.0K | 3.19K | 3.76K | 1.91K | 193K | 83.6K | 420K |
| Total Debt | - | 612K | 2.00M | 13.6M | 17.5M | 19.2M | 20.5M | 11.3M | 5.54M | 5.23M | 4.98M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -180.00 | -3.23M | -264K | -682K | -2.18M | -1.72M | -869K | -341K | -336K | -336K | 659K |
| Capital Expenditure | 0.00 | 8.24M | 47.7K | 7.84K | 161K | 5.44K | 23.2K | 23.2K | 130K | 130K | 209K |
| Free Cash Flow | -180.00 | -11.5M | -311K | -690K | -2.34M | -1.73M | -869K | -341K | -465K | -465K | 450K |
| Ratios | |||||||||||
| ROA | - | -37.4% | -29.0% | -185.2% | -156.1% | -102.9% | -77.5% | 225.7% | -224.0% | -19.3% | -4.2% |
| Net Profit Margin | - | - | - | -326,669.5% | - | - | - | - | -3,015.6% | -153.5% | -81.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CEN Biotech Inc dividends
CEN Biotech Inc has not paid dividends in the last 9 fiscal years.
Who owns CEN Biotech Inc
Ownership data of CEN Biotech Inc is not available yet.
CEN Biotech Inc company profile
- Company name
- CEN Biotech Inc
- Ticker
- CENBF.US
- ISIN
- CA15130L1040
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4
- Fiscal year end
- December
- Address
- 3295 Quality Way, Windsor, ON, Canada, N8T 3R9
- Phone
- 519-419-4958
- Website
- cenbiotechinc.com
About CEN Biotech Inc
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.
CEN Biotech Inc management
2- Mr. Brian S. PayneCEO, CFO, VP, Secretary & Chairman of the Board · born 1968
- Mr. Harold Andre Aubrey De LavenuVP & Independent Director · born 1964